EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.
European Association for the Study of the Liver
https://pubmed.ncbi.nlm.nih.gov/28427875/Actively Recruiting
Led by Nanfang Hospital, Southern Medical University · Updated on 2024-02-20
100
Participants Needed
1
Research Sites
39 weeks
Total Duration
This observational study follows adults with chronic hepatitis B who have experienced a decline in HBsAg levels within the past 12 months. The research aims to describe treatment patterns and assess their impact on HBsAg loss, regardless of whether new molecular entity therapies were used. Participants will be monitored over 36 months, with possible extensions depending on study goals. Patients continue receiving treatment or no treatment based on routine clinical care determined by their physicians. This non-interventional study records medical decisions, treatments, and data without influencing patient care. Follow-up visits occur regularly, typically twice a year or more frequently during specific therapies, and retrospective data from prior visits may also be included. Participants will undergo evaluations including blood sample collection for HBV markers and immune response tests. Researchers will track HBsAg loss at 12 months as the primary outcome, along with other measures over time such as seroconversion rates, liver complications, and quality of life. The study involves ongoing documentation and monitoring aligned with clinical practice, with total participation lasting up to three years or longer.
CONDITIONS
HBsAg Declined Patients Follow-up Study
X
Xieer Liang, M.D.
Z
Zhihong Liu, M.D.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Nanfang Hospital, Southern Medical University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 3 years (36 months after enrollment) with possible extension
Participants who had HBsAg decline in the past 6 months are monitored based on routine clinical practice. Medical decisions and procedures reflect standard care and are documented for study purposes.
Visits approximately every 6 months or more frequently depending on treatment (every 12 weeks during NUC therapy, every 2 to 4 weeks during interferon-α therapy)
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
European Association for the Study of the Liver
https://pubmed.ncbi.nlm.nih.gov/28427875/Maurizia Rossana Brunetto
https://pubmed.ncbi.nlm.nih.gov/20185190/B S BLUMBERG, H J ALTER, S VISNICH
https://pubmed.ncbi.nlm.nih.gov/14239025/Henry Lik-Yuen Chan, Alex Thompson, Michelle Martinot-Peignoux...
https://pubmed.ncbi.nlm.nih.gov/21718667/Nanfang Hospital, Southern Medical University
Lead Sponsor